首页> 美国卫生研究院文献>Acta Pharmacologica Sinica >A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes
【2h】

A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes

机译:扶正化瘀方改善中医证型肝硬化的代谢机理分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fuzheng-Huayu formula (FZHY), a Chinese herbal mixture prescription, has been proven effective in treating liver fibrosis and cirrhosis in both clinical trials and animal experiments. In this study we assessed the metabolic mechanisms of traditional Chinese medicine (TCM) syndrome-based FZHY treatment in liver cirrhosis (LC). A total of 113 participants, including 50 healthy controls and 63 LC patients, were recruited. According to the diagnosis and differentiation of the TCM syndromes, the LC patients were classified into 5 TCM syndrome groups including the liver stagnation syndrome (LSS), spleen deficiency and damp overabundance syndrome (SDDOS), damp-heat accumulation syndrome (DHAS), liver-kidney Yin deficiency syndrome (LKYDS), and blood stagnation syndrome (BSS), and administered FZHY for 6 months. FZHY treatment significantly decreased serum levels of hyaluronic acid (HA), a biochemical marker for LC, as well as TCM syndrome scores (the TCM syndrome scores were decreased in all the groups with significant decreases in the LSS and LKYDS groups). Furthermore, FZHY treatment gradually shifted the metabolic profiles of LC patients from a pathologic state to a healthy state, especially in LC patients with LSS and LKYDS. Twenty-two differently altered metabolites (DAMs) were identified, including carbohydrates, amino acids, fatty acids, etc with 9 DAMs in LSS patients, 9 in LKYDS patients, and 4 in other patients. The metabolic pathways involved in the conversion of amino acids and the body's detoxification process were regulated first, followed by the pathways involved in the body's energy supply process. In conclusion, the evaluation of the effect of TCM syndrome-based FZHY treatment show that FZHY has a better effect on LKYDS and LSS than on the other TCM syndromes, and the metabolic mechanisms might be involved in the increased detoxification function in LKYDS and the improvement of energy supply in LSS, which provides important evidence for the clinical application of TCM syndrome-based treatment.
机译:扶正化瘀方(FZHY)是一种中草药混合处方,在临床试验和动物实验中均被证明可有效治疗肝纤维化和肝硬化。在这项研究中,我们评估了以中医证候为基础的FZHY治疗肝硬化(LC)的代谢机制。总共招募了113名参与者,包括50名健康对照者和63名LC患者。根据中医证型的诊断和鉴别,将LC患者分为肝郁证,脾虚湿盛证,湿热积聚证,肝五类。 -肾阴虚证(LKYDS)和血瘀证(BSS),并给予FZHY 6个月。 FZHY治疗显着降低了血清生化指标透明质酸(HA)的血清水平以及中医证候评分(所有组中的中医证候评分均下降,而LSS和LKYDS组则显着下降)。此外,FZHY治疗逐渐将LC患者的代谢谱从病理状态转变为健康状态,尤其是在LSS和LKYDS的LC患者中。鉴定出22种不同变化的代谢产物(DAM),包括碳水化合物,氨基酸,脂肪酸等,其中LSS患者中9种DAM,LKYDS患者9种,其他患者4种。首先调节与氨基酸转化和人体排毒过程有关的代谢途径,然后对与人体能量供应过程有关的途径进行调节。总之,对以中医证候为基础的FZHY治疗效果的评价表明,FZHY对LKYDS和LSS的疗效优于其他中医证候,其代谢机制可能与LKYDS的排毒功能增强和改善有关。 LSS的能量供应,为中医证候治疗的临床应用提供重要证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号